These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
206 related items for PubMed ID: 33125731
1. Different responses of repetitive behaviours in juvenile and young adult mice to Δ9 -tetrahydrocannabinol and cannabidiol may affect decision making for Tourette syndrome. Gorberg V, McCaffery P, Anavi-Goffer S. Br J Pharmacol; 2021 Feb; 178(3):614-625. PubMed ID: 33125731 [Abstract] [Full Text] [Related]
2. Motor-like Tics are Mediated by CB2 Cannabinoid Receptor-dependent and Independent Mechanisms Associated with Age and Sex. Gorberg V, Borisov V, Greig IR, Pertwee RG, McCaffery P, Anavi-Goffer S. Mol Neurobiol; 2022 Aug; 59(8):5070-5083. PubMed ID: 35666403 [Abstract] [Full Text] [Related]
10. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV. Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187 [Abstract] [Full Text] [Related]
11. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation. Hudson R, Renard J, Norris C, Rushlow WJ, Laviolette SR. J Neurosci; 2019 Oct 30; 39(44):8762-8777. PubMed ID: 31570536 [Abstract] [Full Text] [Related]
12. Interactions between cannabidiol and Δ9 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome. Anderson LL, Low IK, McGregor IS, Arnold JC. Br J Pharmacol; 2020 Sep 30; 177(18):4261-4274. PubMed ID: 32608111 [Abstract] [Full Text] [Related]
13. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. Darmani NA. Pharmacol Biochem Behav; 2001 Feb 30; 68(2):311-7. PubMed ID: 11267636 [Abstract] [Full Text] [Related]
15. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, Emrich HM. Pharmacopsychiatry; 2002 Mar 30; 35(2):57-61. PubMed ID: 11951146 [Abstract] [Full Text] [Related]
16. Absence of interaction between delta9-tetrahydrocannabinol (delta-THC) and cannabidiol (CBD) in aggression, muscle control and body temperature experiments in mice. Ham MT, De Jong Y. Psychopharmacologia; 1975 Mar 30; 41(2):169-74. PubMed ID: 1171491 [Abstract] [Full Text] [Related]
19. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, Saunders R, Freeman TP. Neurosci Biobehav Rev; 2019 Dec 30; 107():696-712. PubMed ID: 31580839 [Abstract] [Full Text] [Related]
20. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O' Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. Neuropsychopharmacology; 2010 Feb 30; 35(3):764-74. PubMed ID: 19924114 [Abstract] [Full Text] [Related] Page: [Next] [New Search]